Advertisement

Open Payments data show docs got most (by far) from Genentech

By Modern Healthcare  |  July 01, 2015

Genentech, the maker of Avastin and other expensive cancer drugs, paid physicians and teaching hospitals more than any other drug or device company in 2014, according to a new round of data posted to the CMS' Open Payments website.

CHI's latest financials show road to growth can be bumpy

By Modern Healthcare  |  July 01, 2015

In an industry that's been rapidly consolidating, Catholic Health Initiatives has had a particularly rapid growth trajectory. The system has strained to contain costs associated with acquiring new hospitals. But CHI is improving in its core business, which could bode well for its full-year results.

IOM: The doctor will see you TODAY should be standard

By Modern Healthcare  |  July 01, 2015

Provider-focused approaches to scheduling and failure to appropriately use nurse practitioners and physician assistants are among the reasons timely access to care remains a problem in the U.S., according to an Institute of Medicine report.

High court case could threaten union finances at public systems

By Modern Healthcare  |  July 01, 2015

The U.S. Supreme Court will hear a case asking it to limit the power of public unions to collect fees from nonmembers. The case could threaten the finances and membership efforts of unions that represent healthcare workers at publicly owned providers.

Deadline nearing for IMPACT Award entries

By Modern Healthcare  |  July 01, 2015

Modern Healthcare and Advertising Age are accepting entries for the second annual Healthcare Marketing IMPACT Awards, and the July 7 deadline is approaching fast. The program recognizes healthcare's best advertising, marketing, promotion and communication campaigns across all media platforms.

IOM reports 'unacceptable' disparities in cardiac arrest survival

By Modern Healthcare  |  July 01, 2015

A report from the Institute of Medicine suggests revamping the national strategy for cardiac arrest to standardize surveillance, coordination, data collection, public education and the sharing of best practices pertaining to the condition.

Open Payments data show docs got most (by far) from Genentech

Open Payments data show docs got most (by far) from Genentech

By Art Golab and Michael Sandler  |  June 30, 2015

Genentech, the maker of Avastin and other expensive cancer drugs, paid physicians and teaching hospitals more than any other drug or device company in 2014, according to a new round of data posted to the CMS' Open Payments website.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.